PharmaEssentia Corporation
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 6446.TW | 4547.T | IPCALAB.NS | GLENMARK.BO | 0MTD.IL | 300558.SZ | |
|---|---|---|---|---|---|---|
| Market cap | 490.25B | 161.53B | 494.62B | 701.47B | 178.69B | 20.76B |
| P/E (TTM) | 68.2 | 14.4 | 37.8 | 39.0 | 50.8 | 77.9 |
| Forward P/E | 27.0 | 17.6 | 27.7 | 25.6 | — | 29.2 |
| Price/book | 13.3 | 0.7 | 6.1 | 6.7 | 5.2 | 3.2 |
| Dividend yield | 0.12% | 3.46% | 0.30% | 0.20% | — | 0.31% |
| 1-year change | +179.84% | −6.36% | +51.13% | +38.17% | +46.92% | −12.57% |
| Today | −5.20% | +3.06% | −1.14% | −0.65% | +2.36% | +1.62% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 20 min.
Latest news
All 6446.TW news ›PharmaEssentia seeks to expand access to blood cancer drug in Europe
Taipei, Nov. 4 (CNA) Taiwan-based drugmaker PharmaEssentia Corp. is seeking to expand patient access to its blood cancer drug Ropeg in Europe, where the treatment has yet to receive regulatory approval for essential thrombocythemia (ET),…
PharmaEssentia’s Ropeg Expands Global ET Approvals While Europe Awaits Regulatory Clearance
Eagle-Tribune Dr. Jack Hwang, General Manager of PharmaEssentia Corp. and Representative of PharmaEssentia Corp. Taichung office. TAIPEI, Taiwan--(BUSINESS WIRE)--Nov 3, 2026-- PharmaEssentiaâs blood cance
PharmaEssentia to Participate in Upcoming Jefferies and Citi Healthcare Conferences
BioSpace PharmaEssentia to Participate in Upcoming Jefferies and Citi Healthcare Conferences BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446
PharmaEssentia to Present Data at 18th International Congress on Myeloproliferative Neoplasms Highlighting Unmet Need with Current Therapies and Real-World Use of BESREMi® in Essential Thrombocythemia and Polycythemia Vera
More than half of patients with polycythemia vera remained on first-line BESREMi at two years in real-world practice All six posters will be presented during the Congress poster session on October 29 at 5:45 p.m. ET. Title: Real-World…
From Taiwan to the World: PharmaEssentia Expands Global Reach With New Drug Approvals, Overseas Investments
PharmaEssentia Corporation (TWSE: 6446), a Taiwan-based biopharmaceutical company, is expanding its global presence through new drug approvals, clinical trials and overseas investments, as it seeks to bring its Taiwan-developed innovative…
PHARMAESSENTIA
Black Hills Pioneer From Taiwan to the World: PharmaEssentia Builds a Scientist-Led, Fully Integrated Global Biopharmaceutical Company with Patients at Its Core There was a problem reporting this. Keep it Clean. Please avoid obscene,…
ITRI-501 Licensed to PharmaEssentia : Accelerating a New Drug From R&D to the Clinic
Industrial Technology Research Institute ITRI-501 Licensed to PharmaEssentia : Accelerating a New Drug From R&D to the Clinic Cancer immunotherapy is a major focus of global drug development, but progressing from t
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- gazettextra.com3
- bhpioneer.com2
- aol.com1
- biospace.com1
- eagletribune.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.